Pipeline
Our R&D portfolio currently consists of:
- New Chemical Entities in various fields, such as neurology and analgesia.
- New Advanced Therapies for inherited metabolic disorders.
Our portfolio and continued commitment to R&D, together with our manufacturing capacity, have allowed us to receive an "Excellent" rating in Group A of the Spain's Profarma Plan (Plan to Promote Scientific Research, Technological Development and Innovation in the Pharmaceutical Industry) continuously since 1986.
ESTEVE is implementing various programs that are currently in diverse stages of research and development.
Small Molecule Gene therapy
Moderate-to-Severe Acute Pain
E-58425: a novel, first-in-class co-crystal of Celecoxib and Tramadol
July 2019 update: United States Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for E-58425.
Neuropathic Pain
E-52862: a novel, first-in-class NCE selective Sigma-1 antagonist
Mucopolysaccharidosis Type IIIA
EGT-101: a potential first-in-class AAV-9 gene therapy administered via a one-time intracerebroventricular injection into the cerebrospinal fluid
General information about Sanfilippo Syndrome Type A or mucopolysaccharidosis (MPS) IIIA.
See more 
Pain-Related Disorders (Undisclosed)
MUMO-1: a novel, first-in-class NCE with a multi-modal mechanism of action that includes Sigma-1 antagonism
Mucopolysaccharidosis Type IIIB
EGT-201: a potential first-in-class AAV-9 gene therapy
Mucopolysaccharidosis Type II
EGT-301: a potential first-in-class AAV-9 gene therapy
Undisclosed
MUMO-5: a novel, first-in-class NCE with multimodal mechanisms of action
Lysosomal Storage Disorder (Undisclosed)
A potential first-in-class gene therapy
Neurodegenerative Disorders (Undisclosed)
Unique Sigma-1 Platform of agonists and antagonists
